Last reviewed · How we verify
QLC1101
At a glance
| Generic name | QLC1101 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Food Effect on Pharmacokinetics Study of QLC1101 in Healthy Subjects (PHASE1)
- A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation (PHASE1, PHASE2)
- A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLC1101 CI brief — competitive landscape report
- QLC1101 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI